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Enteric nervous systemThe neural crest-derived cell population that colonizes the bowel (ENCDC) contains proliferating neural/glial
progenitors. We tested the hypothesis that bonemorphogenetic proteins (BMPs 2 and 4), which are known to
promote enteric neuronal differentiation at the expense of proliferation, function similarly in gliogenesis.
Enteric gliogenesis was analyzed in mice that overexpress the BMP antagonist, noggin, or BMP4 in the
primordial ENS. Noggin-induced loss-of-function decreased, while BMP4-induced gain-of-function increased
the glial density and glia/neuron ratio. When added to immunoisolated ENCDC, BMPs provoked nuclear
translocation of phosphorylated SMAD proteins and enhanced both glial differentiation and expression of the
neuregulin receptor ErbB3. ErbB3 transcripts were detected in E12 rat gut, before glial markers are expressed;
moreover, expression of the ErbB3 ligand, glial growth factor 2 (GGF2) escalated rapidly after its ﬁrst
detection at E14. ErbB3-immunoreactive cells were located in the ENS of fetal and adult mice. GGF2
stimulated gliogenesis and proliferation and inhibited glial cell derived neurotrophic factor (GDNF)-promoted
neurogenesis. Enhanced glial apoptosis occurred following GGF2 withdrawal; BMPs intensiﬁed this GGF2-
dependence and reduced GGF2-stimulated proliferation. These observations support the hypotheses that
BMPs are required for enteric gliogenesis and act by promoting responsiveness of ENCDC to ErbB3 ligands
such as GGF2.630W 168th Street, New York,
).
l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
The enteric nervous system (ENS) is the largest and most complex
division of the peripheral nervous system (PNS) (Furness, 2006;
Gershon and Ratcliffe, 2006). Its component neurons are phenotyp-
ically diverse and form microcircuits that allow the ENS to regulate
the behavior of the bowel independently of input from the brain and/
or spinal cord (Gershon and Tack, 2007). Like the brain, the ENS lacks
internal collagen and derives support for its neuronal elements from
glia that resemble their counterparts in the central nervous system
(CNS)(Gershon and Rothman, 1991). The ENS develops from
precursors that migrate to the bowel from vagal, rostral truncal, and
sacral levels of the neural crest (Burns and Le Douarin, 1998; Durbec
et al., 1996; Heanue and Pachnis, 2007; Kapur, 2000; Le Douarin and
Teillet, 1973; Le Douarin and Teillet, 1974; Pomeranz and Gershon,
1990; Pomeranz et al., 1991). Althoughmany individual crest-derived
cells are already determined before they reach the bowel (Henion and
Weston, 1997; Pham et al., 1991; Reedy et al., 1998a,b), the enteric
population of crest-derived cells (ENCDC) is multipotent (Natarajanet al., 1999). This population responds to growth factors and other
components of the enteric microenvironment, the actions of which
are responsible for the development of the unique properties of the
ENS (Gershon and Ratcliffe, 2006; Heanue and Pachnis, 2007).
It is likely that the early ENCDC population contains precursors
that are common both to neurons and to glia (Natarajan et al., 1999;
Young et al., 2003, 2005). Relatively little is known about signals that
act on these uncommitted precursors to cause them to differentiate
and give rise to divergent neuronal and glial cell lineages. Early ENCDC
express both Phox2b and Sox10; however, ENCDC that commit to a
neuronal lineage downregulate Sox10 expression while maintaining
Phox2b (Pattyn et al., 1997; Young et al., 1999, 2003). Conversely
ENCDC committed to a glial lineage downregulate Phox2b expression
while maintaining Sox10 (Bondurand et al., 2006; D'Autreaux et al.,
2007; Deal et al., 2006; Kim et al., 2003; Paratore et al., 2001;
Stanchina et al., 2006). Sox10, moreover, controls expression of ErbB3
(Britsch et al., 2001) and enteric glia are absent inmice that lack ErbB3
(Riethmacher et al., 1997), suggesting that this receptor is important
in enteric gliogenesis. The neuregulin (Nrg) family of ligands signals
through ErbB receptors (Birchmeier, 2009; Brinkmann et al., 2008).
Nrgs are produced by mesenchymal cells and promote glial lineage
commitment by primary neural crest cells in vitro at the expense of a
neuronal fate (Shah and Anderson, 1997; Shah et al., 1994). Only one
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isoform) is a secreted molecule (Marchionni et al., 1993); it promotes
development of satellite cells, which are in a glial lineage, in
developing sensory ganglia (Leimeroth et al., 2002).
During early fetal life, ENCDCs respond to and require stimulation
by glial cell derived neurotrophic factor (GDNF), which promotes
proliferation, differentiation, survival, and migration of enteric
precursors (Asai et al., 2006; Chalazonitis et al., 1998a; Hao and
Young, 2009; Hearn et al., 1998; Laranjeira and Pachnis, 2009; Young
et al., 2001). The ability of GDNF to stimulate proliferation declines as
a function of fetal age (Chalazonitis et al., 1998a) and is limited by the
actions of BMP-2 and -4 (Chalazonitis et al., 2004). These BMPs
oppose GDNF by enhancing differentiation at the expense of the
continued proliferation of precursors. BMPs also induce the expres-
sion of certain growth factor receptors, such as TrkC, thereby
promoting responsiveness to and dependence on their corresponding
ligands, which in the case of TrkC is NT-3. This action of BMP signaling
favors the development of some phenotypes of enteric neuron, such
as NT-3/TrkC-dependent dopaminergic neurons, at the expense of
others (Chalazonitis et al., 2004, 2008).
AlthoughBMP-2and -4 increase enteric neuronaldifferentiation, it is
not clear whether or not they also enhance development of enteric glia.
We therefore tested the hypothesis that BMPs stimulate uncommitted
ENCDC to differentiate but do not determine whether they develop as
neurons or glia. We postulated that this lineage choice instead depends
on other factors, such as GDNF and GGF2, which promote, respectively,
neuronal and glial development. Speciﬁcally, we proposed that a
balance exists between Ret activation by GDNF, which favors the
expansion of cells in a neuronal lineage, and ErbB3 activation by a Nrg
such as GGF2, which expands the population in a glial lineage. Our
observations support these hypotheses and indicate that BMPs enhance
the responsiveness of ENCDC both to GDNF-induced neurogenesis and
GGF2-induced gliogenesis. Portions of this work have previously been
published in abstract form (Chalazonitis et al., 2007, 2009).
Materials and methods
Animals
Pregnant female rats (Sprague–Dawley; Charles River laboratories,
Waltham MA) were subjected to CO2 narcosis and killed by
thoracotomy. The Animal Care and Use Committee of Columbia
University approved these procedures. Gestational age was counted
from the occurrence of a vaginal plug, which was considered E0. The
entire gut, from stomach to rectum, was dissected as a single
specimen under aseptic conditions. To isolate crest-derived cells,
these specimens were pooled from 30 to 32 fetuses at E12, 20–25
fetuses at E14, and 15–20 fetuses at E16. Pregnant female mice (CD-1;
Charles River) were euthanized as described above.
Transgenic mice
The neuron speciﬁc enolase (NSE) promoter was employed to
overexpress noggin or BMP4 in the gut of transgenic animals
(Chalazonitis et al., 2004; Gomes et al., 2003; Guha et al., 2004). An
IRES–GFP sequence allows expression of the noggin transgene to be
monitored by demonstrating the native ﬂuorescence or immunoreac-
tivity of GFP. GFP expression was not detectable in the gut of transgenic
mice at E13, although it was observed to be present in the primordia of
prevertebral sympathetic ganglia and chromafﬁn bodies. GFP was
abundantly expressed in the gut by E16 and was maintained through
P11, not only in the ENS, but also in scattered epithelial cells. By P0, GFP
ﬂuorescence was also exhibited by many cells in the subepithelial
mesenchyme(Chalazonitis et al., 2008). Theseobservations suggest that
the onset of transgenic overexpression of noggin in the gut begins
betweenE13 and E16 and persists into postnatal life. Although theNSE–BMP4 construct did not have an IRES–GFP sequence and thus was not
speciﬁcally labeled, immunoblots at E16 revealed that the level of BMP4
expression was higher than that of WT animals (Gomes et al., 2003).
RT-PCR
Pairs of oligonucleotide primers for ampliﬁcation of cDNAs
encoding GGF2, ErbB3, p75NTR and β-Actin1 were designed from
published rat cDNA sequences. The Gene bank accession number, the
sequences of the primers used for PCR, the conditions of ampliﬁcation
and the expected sizes of the products are shown in Table 1. The
identities of all PCR products were conﬁrmed by sequence analysis.
For this purpose, PCR products were subcloned into pGEM-T Easy
vectors (Promega, Madison, WI) using the TA-cloning kit (Invitrogen
Corporation, Carlsbad, CA). Inserts in two individual clones were
sequenced by the dideoxynucleotide-chain termination method in
the DNA Facility of Columbia University. The sequences of the PCR
products obtained from brain and gutwith the indicated primerswere
found to be identical to those of the appropriate regions of the
GenBank sequences of the ampliﬁed cDNAs (Table 1).
Real time PCR
Real time PCRwas used to quantify transcripts encoding GGF2 in the
fetal and adult rat gut. Primers for GGF2 were chosen to amplify a PCR
product that includes the Kringle domain, which is unique to GGF2
(Buonanno and Fischbach, 2001). The expression of GGF2 was
normalized to that of β-actin1. Transcripts encoding β-actin1 and
GGF2were quantiﬁed by real time PCR (RT PCR)with a SYBR Green I kit
(Roche Diagnostics Corporation, Indianapolis, IN) and Jumpstart Taq
ReadyMix (Sigma, St. Louis, MO) using a LightCycler™2.0 instrument as
previously described (Chalazonitis et al., 2008; D'Autreaux et al., 2007).
Ampliﬁcationswere carried out in a ﬁnal volume of 20 μl that contained
Taq DNA polymerase, reaction buffer, dNTPs in which dTTP is replaced
by dUTP, SYBR Green I dye, and MgCl2. The ﬁnal concentration of
primers used for the ampliﬁcation of cDNA encoding β-actin1 or GGF2
was 0.5 μM. The ﬁnal concentration of MgCl2 was 4.0 mM. To this
mixture 1 μl of either the serially diluted plasmid PGEM-T with the
inserted PCR product DNA (standards) or the cDNA prepared from
tissuewas added.Measurementswere obtainedby referring to standard
curves that were prepared by serially diluting plasmid DNA containing
an insert of a PCR product that includes a portion of the sequence of
GGF2 or β-actin1. The dilutions of β-actin1 and GGF2 plasmid DNA
ranged from 1 ng to 100 fg in 5 series, each of which covered a 10-fold
range. The standards and the cDNA from tissues were simultaneously
subjected to RT PCR analysis in parallel capillary tubes. A ﬁrst
denaturation step for each round of PCR was carried out at 94oC for
10 min to activate the polymerase. The PCR reactions were carried out
according to theprograms inTable 1. The appearanceof double stranded
DNAwas quantiﬁed bymeasuring the ﬂuorescence of SYBR Green after
each step of elongation. The ramp rate was 20 °C/s during the
ampliﬁcation program. A melting curve analysis with a ramp rate of
0.1 °C/swas carriedout toverify that a singlemoietyhadbeenampliﬁed.
Data were analyzed with computer assistance employing the Light-
Cycler™ software. Three independent experiments for GGF2 and 2
independent experiments for β-actin1 were carried out. The sequences
of the products obtained from gut with the indicated primers (Table 1)
were found to be identical to those of the appropriate regions of the
GenBank sequence of Nrg1 type 2 ampliﬁed cDNAs.
Immunoselection
Crest-derived cells were immunoselected from the fetal rat gutwith
antibodies to the common neurotrophin receptor, p75NTR, at E12, E14
andE16asdescribedpreviously (Chalazonitis et al., 1998a,b, 2001, 2004,
2008). Brieﬂy, the bowelwasdissociatedwith collagenase. The resulting
Table 1
PCR primers, conditions used for ampliﬁcation, and expected sizes of PCR products.
Protein Sense (5′-3′)/Nucleotides Antisense (5′-3′)/Nucleotides Cycles Temperature °C (time s)/*Annealing Temp Product (bp)
GeneBank#
Rat GGF2/Nrg1 type II GGTGGTGATCGAGGGA CGGTGAGTAGCGAGTC 40 94 (5 s), 57⁎ (10 s), 72(12 s) 275
AF 194994 424–439 698–683 Kringle domain
Rat ErbB3/Her3 TGTCGAAACTACAGCCG ACCGTCACCGCTATTAC 35 94 (30 s), 55⁎ (45 s), 72 (45 s) 386
U 29339.2 1696–1712 2081–2065
Rat p75NTR/Ngfr GAGGGCACATACTCAGACGAAGCC GTCTATATGTTCAGGCTGGTAACC 30 94 (30 s), 60⁎ (45 s), 72 (45 s) 663
NM 012610 567–590 1229–1206
Rat β-Actin1/Actb TGTTTGAGACCTTCAACAC CAGTAATCTCCTTCTGCATCC 40 94(5 s), 58⁎ (10 s), 72(23 s) 586
NM031144 449–467 1035–1015
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(Table 2) and then to secondary antibodies coupled to magnetic beads
(Miltenyi Biotec Inc Auburn, CA). The antibody decorated crest-derived
cells were ﬁnally selected with a magnetic ﬁeld. This procedure
positively selects crest-derived cells,which are retainedby themagnetic
ﬁeld, and negatively selects non-crest-derived cells, which pass through
it. Both themonoclonal (MC192; donated byDr. Robert A. Rush, Flinders
University) and polyclonal antibodies to p75NTR (donated by Dr. Moses
Chao; Skirball Inst. New York University) that were used for
immunoselection react with the extracellular domains of mouse and
rat p75NTR (Chandler et al., 1984; Huber and Chao, 1995).
Tissue culture
Crest-derived cells were plated at a density of 1.2×105 cells/ml onto
12 mm diameter glass coverslips (RESY No. 1001, Germany) that wereTable 2
Antibodies used to identify enteric glia and neurons.
Antigen/Species Host Dilution
p75NTRextracellular domain/mouse Rabbit polyclonal 1:1000⁎
1:2000
p75NTR/rat PC12 membranes Mouse monoclonal clone MC192 20 μg/ml⁎
BFABP recombinant protein/mouse Rabbit polyclonal 1:170
S100 (A and B) Rabbit 1:1000
Cow brain Polyclonal 1:2000 (w
S100 β puriﬁed recombinant protein/Human Rabbit polyclonal 1:400 (cul
GFAP puriﬁed/bovine Rabbit polyclonal 1:1000 (cu
GFAP puriﬁed glial ﬁlament/human Mouse monoclonal clone G-A-5 1:150 (cul
GFAP puriﬁed Chicken IgY
Polyclonal 1:1000 (se
PH-3 peptide (aa7-20) of PHistone-3/Human Rabbit polyclonal 1:200 (cul
ErbB3 p160 (17aa peptide in last 50 aa of
C-terminal domain)/Human
Mouse monoclonal Clone G4 1:50 (cult
ErbB3 (19aa peptide of N-terminal
domain/Human
Rabbit polyclonal 1:50 (sect
Sox10, epitope ﬁrst 65 aa/mouse or rat Mouse monoclonal Clone 20B7 1:10
pSmad1,5,8 peptide residues around P
Ser 463/465 and P Ser426/428/Human
Rabbit polyclonal 1:100
HuC/HuD, RNA binding protein of the
Elav family/Human
Mouse monoclonal biotinylated
clone 16A11
1:50
PGP 9.5 puriﬁed from brain/Human Rabbit polyclonal 1:800
⁎ Dilution used for immunoselection.coated with poly-D-lysine, rat tail collagen and laminin, as described
previously (Chalazonitis et al., 1998b). Cultures were maintained in a
deﬁnedmedium (Basic Brazeau; BBM) (Ziller et al., 1983). At the timeof
plating, the medium was supplemented with 20% horse serum (JRH,
Lenexa, KA) to promote adherence of cells to the substrate. After 18 h,
this medium was changed to serum-free BBM. When cultures were
maintained for longer than 4 days, theywere fedwith freshmediumon
the 4th day. In all experiments, the factors to be studied, which included
BMPs-2 and -4 (human recombinant; Wyeth, Cambridge MA and R&D
systemsBerkeley CA), GGF2(AcordaTherapeutics, Hawthorne, NY), and
GDNF (rat recombinant; R&D Systems), were added to the medium at
the time of plating or of medium change and were present throughout
the culture period. Control cultureswere supplementedwith thevehicle
inwhich thegrowth factorswerediluted (0.5% bovine serumalbumin in
BBM). At least 4 replicate cultures were studied for each condition in
each experiment.Source References
Moses Chao, Skirball Institute New York
University, NY
Huber and Chao, 1995;
Chalazonitis et al., 2008
Robert A. Rush, Flinders University,
Adelaide, Australia
Chandler et al., 1984;
Chalazonitis et al., 2001
Thomas Müller, Max Delbrück Center for
Molecular Med., Berlin Germany
Kurtz et al., 1994;
Young et al.,
2003
DAKO Glostrup Denmark Young et al., 2003
holemount) Cat# Z 0311
tures) Cat# A 5110
ltures) Chemicon/Millipore Jungling et al., 2003
Temecula, CA
Cat# AB5804
tures) Chemicon/Millipore Cat#MAB3402 Yang et al., 2005
ctions) Neuromics, Edina MN, Cat# CH22102 Liu et al. 2009
tures) Upstate, cell signal. solutions/Millipore Bondurand et al., 2003
Lake Placid, NY
Cat#06-570
ures) Santa Cruz Biotechnology, Inc. Santa Cruz, CA
Cat# SC-7390
Ritch et al., 2003
ions) Abnova, Taiwan Corp. Taipei, ROC
David J. Anderson, California Institute of
Technology HHMI, CA
Lo et al., 2002
Cell Signaling Technology, Inc. Beverly, MA
Cat#9511
Ahn et al., 2001
Molecular Probes, Eugene, OR Cat# A21272 Wakamatsu et al., 2001
Biogenesis Ltd, Poole,UK Wilkinson et al., 1989
Cat#7863-0504
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Immunocytochemical detection of markers was used to identify
neurons and glia differentiating in vitro (Chalazonitis et al., 2001,
2004). Cultures were ﬁxed for 1 h (or 15 min to demonstrate the
mitotic marker phospho-histone-3) with 4% formaldehyde (freshly
prepared from paraformaldehyde) in 0.1 M PBS and permeabilized
with 0.1%Triton X. The cultures were then processed and examined asFig. 1.Over-expression of noggin in the developingmouse ENS reduces glial density and the g
bowel served as a glial marker. A. Glial density in the ileal myenteric plexus of WT and tran
n=37), homozygotes (Nog/Nog, n=34). *pb0.05 Nog/+ and pb0.001 Nog/Nog. B. Glial den
were WT (n=49), Nog/+ (n=34), Nog/Nog (n=29). *pb0.05. C–E. Neurons and glia (arr
(Nog/Nog) and WT mice. Scale bar=30μm. Neurons were identiﬁed by staining with cupro
(D, E). F–H Submucosal plexus. F. Cuprolinic blue staining in a Nog/Nog mouse. (G, H) Cu
(H) littermates. I. The ratios of glia to neurons in the duodenal myenteric plexus. The number
neurons in the ileal myenteric plexus. The numbers of measurements were in WT (n=42),
glia to neurons in the ileal submucosal plexus. The numbers of measurements were WT (nwhole mounts. Fixed cultures were incubated with primary anti-
bodies (Table 2) at room temperature overnight (or for 48 h at 4 °C to
demonstrate ErbB3). Bound antibodies were detected with species-
speciﬁc secondary antibodies labeled with Alexa 488, Alexa 594
(Molecular Probes, Eugene, OR), or biotin (Kirkegaard & Perry,
Gaithersburg, MD). Biotinylated antibodies were visualized with
streptavidin coupled to Alexa 594 (Molecular Probes). Controls
included immunostaining in the absence of primary antibodies. DNAlia to neuron ratio. S100β immunoreactivity inwholemounts of laminar preparations of
sgenic mice. The numbers of measurements were WT (n=57), heterozygotes (Nog/+;
sity in the submucosal plexus ofWT and transgenic mice. The numbers of measurements
owheads) in the myenteric plexus of the ileum of homozygous noggin overexpressing
linic blue without (C, F) or together with simultaneous co-immunostaining for S100β
prolinic blue and S100β immunoreactivity are demonstrated in Nog/Nog (G) and WT
s of measurements wereWT (n=16), Nog/+ (n=33); *pb0.0001. J. The ratios of glia to
in Nog/+ (n=27), and in Nog/Nog (n=15); *pb0.01 compared to WT. K. The ratios of
=34), Nog/+ (n=24), and Nog/Nog (n=18); *pb0.01 compared to WT.
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facilitate counting nuclei to determine the total number of cells/
culture. Terminal deoxynucleotidyl transferase (TdT)-mediated bio-
tinylated UTP nick end labeling (TUNEL method; TACS™ Apoptosis
Detection Kit; R&D Systems, Minneapolis, MN) was used to identify
cells undergoing apoptosis (Chalazonitis et al., 2004). When used to
identify apoptotic glia, GFAP immunoreactivity was demonstrated
prior to application of the TUNEL method.
Gut was dissected from E17 and adult CD-1mice and ﬁxed with 4%
formaldehyde (freshly prepared from paraformaldehyde) in 0.1 M
phosphate buffer for 4 h. After rinsing, the gut was immersed in 30%
sucrose overnight followed by immersion in embedding medium
(Neg50, Richard-Allan Scientiﬁc, Kalamazoo, MI) and frozen in blocks.
Sections (10–12 μm thick) were cut in a cryostat-microtome and
dried on Superfrost slides (Fischer Scientiﬁc, UK). Immunocytochem-
istry for neuronal and glial markers (see Table 2) followed procedures
similar to those used for cultured cells, except that the Triton X
concentration was 0.3%.
Laminar preparations of gut wall
Bowel was removed from NSE–Nog and NSE–BMP4 mice and their
WT littermates and dissected to obtain laminar preparations of the
wall of the small intestine (duodenum and ileum) (Chalazonitis et al.,
2004, 2008). Layers containing the submucosal and myenteric
plexuses were analyzed separately. These preparations were ﬁxed
as described above, processed, and examined as whole mounts.
Immunoreactivity of S100β (Table 2) was used to identify glia.
Primary antibodies were applied overnight at room temperature.
Secondary antibodies were labeled with horseradish peroxidase
(HRP). Endogenous peroxidase activity was blocked with 0.3% H2O2
in PBS. Peroxidase activity was visualized with H2O2 and 3, 3′-Fig. 2. The density of glial cells and the glia to neuron ratio are increased in myenteric plex
enteric glial cells in whole mounts of laminar preparations of bowel containing the myenter
immunostained glial cell body (arrow). Cuprolinic blue counterstaining. This is the type of pr
immunostained neurons. B. Heterozygous NSE–BMP4 (BMP4/+) mouse. The ganglia
immunoreactivity of enteric glia. The clear lacunae in the glial network are the non-immunos
(see Panel A inset) and expressed as % of WT. D. The glial density was normalized to that of
expressed as a glia/neuron ratio. Both the glial density and the glia/neuron ratio were signdiaminobenzidine with or without nickel intensiﬁcation (Vector
laboratories, Burlingame, CA). To simultaneously demonstrate glia
and neurons, the neurons were stained ﬁrst for 1 h at 37 °C with
cuprolinic blue (0.5% in 0.05 mM Na acetate buffer, pH5.6, containing
1.0 mMMgCl2) (Chalazonitis et al., 2004; Karaosmanoglu et al., 1996;
Phillips et al., 2004).
Immunostained cultures, sections, or laminar preparations of
bowel wall were analyzed and photographed with a Leica DMRXA2
microscope equipped with dichroic mirror/ﬁlter assemblies that
permitted no-cross detection of bisbenzimide, Alexa 488 and Alexa
594 ﬂuorescence. Images were captured with a cooled CCD camera
(Retiga Exi) mounted on the microscope and analyzed with Improvi-
sion software (Lexington, MA).
Quantitation of glia and neurons
Neurons, glia, and total numbers of cells developing in culture
were identiﬁed as described above and quantiﬁed. Both the absolute
numbers of each cell type and their proportion of the total number of
cells in each culture were thus ascertained. When the quantitative
data for identiﬁed cell types are presented, they were normalized,
most often as a percent of vehicle to facilitate comparison of different
experimental conditions and of repeated experiments. When total
numbers of cells changed, data were often shown both as a proportion
of total cells and as a percent of vehicle. When necessary data were
normalized to the numbers of a particular type of cell; These methods
have been previously published (Chalazonitis et al., 2001, 2004).
Similarly, the packing densities of glia and neurons, identiﬁed in
laminar preparations as described above, were determined and
expressed as a function of tissue area (mm2). Individual measure-
ments (n) were deﬁned as the sum of glia or neurons counted, using a
40X objective, in 10 contiguous, non-overlapping ﬁelds covering anus of mice over-expressing BMP4. The immunoreactivity of S100β was used to identify
ic plexus. A. WT mouse. Inset: A high magniﬁcation image of the cell body of an S100β-
eparation used to quantify glia; note that glial processes wrap around the light blue non-
and connectives of the myenteric plexus are made visible by the brown S100β
tained neurons. The bars=60 μm. C. The glial density (glia/mm2 plexus) was quantiﬁed
neurons (marked by staining with cuprolinic blue [see Figs. 1 and 2A inset, above]) and
iﬁcantly greater in BMP4/+ than in WT mice. *pb0.001, n=12.
69A. Chalazonitis et al. / Developmental Biology 350 (2011) 64–79area of 1.254 mm2. The packing densities of neurons and glia in the
small intestines of NSE–Nog and NSE–BMP4mice at ages P26–34were
compared to those measured in their WT littermates. For NSE-Nog,
small intestines were obtained from 9 heterozygotes (NSE–Nog/+), 5
homozygotes (NSE–Nog/Nog), and 5 WT littermates. For NSE–BMP4
mice, 4 heterozygotes and 4 WT littermates were studied.
Statistical analyses
Data are expressed as means±standard errors and were com-
pared using ANOVA (Prism 4.0b for the Macintosh computer;
GraphPad Software, Inc.). Post hoc analysis was carried out with the
Tukey–Kramer test for multiple comparisons. The Bonferroni test was
employedwhen only 3 groupswere compared. An unpaired t-test was
carried out to compare one group with another.Fig. 3. BMPs promote gliogenesis in vitro. ENCDC were immunoisolated from rat fetal bowel
presence of vehicle, low (0.5–1 ng/ml) or high (20 ng/ml) concentrations of BMP-2 or -4. A
was used as the glial marker at E12, while S100β and GFAP served as glial markers at E14 a
preparations immunostained with antibodies to S100β and GFAP, data obtained with thes
expressing glial markers in vehicle-treated cultures. *pb0.05 vs. vehicle. The high concentra
E14 and E16. B–D. Illustrations of glia (arrows), marked with GFAP immunoreactivity (gree
bisbenzimide (blue). The conditions were vehicle (B), low BMP4 (C), and high BMP4 (D)
gliogenesis. E. Illustration of glia developing from crest-derived cells immunoselected at E16
the presence of low BMP2. The bar=30 μm.Results
Transgenic overexpression of noggin under control of the NSE-promoter
(NSE–Nog) impedes development of enteric glia
The packing densities of glia in the duodenum and ileum of NSE–
Nog/+ and NSE–Nog/Nog mice were compared to that in WT
littermates (Figs. 1A, B). Laminar preparations containing, respectively,
the myenteric (Figs. 1C–E) and submucosal plexuses (Figs. 1F–H), were
examined immunocytochemically as whole mounts using S100β as a
glial marker (Figs. 1D, E, G, and H). The glial packing density was
signiﬁcantly higher inWT than in either NSE–Nog/+ (pb0.05) or NSE–
Nog/Nog mice (pb0.001) (Figs. 1A, B). No difference, however, was
observed between the NSE–Nog/+ andNSE–Nog/Nog animals. Because
neuron numbers are greater in both types of transgenic mouse than inwith antibodies to p75NTR at E12, E14, and E16. Cultures were treated for 5 days in the
. The numbers of cells in a glial lineage were quantiﬁed immunocytochemically. BFAPB
nd E16. Because no differences were found in glial numbers at E14 or E16 in counts of
e two markers was pooled. Data at each age were normalized to the numbers of cells
tion of BMPs was most effective at E14. BMP-stimulated gliogenesis declined between
n), developing from crest-derived cells immunoselected at E14. DNA was stained with
. Note that increasing concentrations of BMP promote aggregation of cells as well as
. Glia are nowmarked with S100β-immunoreactivity (green) and have been cultured in
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neurons, demonstrated with cuprolinic blue (Figs. 1C–H), in the two
plexuses were also determined and used to normalize the densities of
enteric glia. The glia/neuron ratio inmyenteric ganglia ofwild-typemice
was found to be signiﬁcantly higher (pb0.0001) in the ileum (1.00±
0.02;n=42) than in theduodenum(0.52±0.02;n=32); therefore, theFig. 4. BMP4 induces phosphorylation and nuclear translocation of Smad 1/5/8 in cultured en
Smad proteins was studied in glia developing in vitro from ENCDC immunoisolated from E16
of 1 h to vehicle, BMP4 (20 ng/ml) or BMP4 plus noggin (100 ng/ml). Smad phosphory
phosphorylated forms of the receptor activated Smads 1, 5, and 8 and glia were simultaneou
in which the nuclear translocation of phosphorylated Smadwere detected were quantiﬁed in
effect of BMP4, the ordinate is displayed as a logarithmic scale. The translocation of pSmad
exposed only to vehicle. (n=4 cultures each). Noggin blocked the BMP4-induced nuclear tra
BMP4 (D, E), and BMP4+noggin (F, G). The images at the left (B, D, and F) show the ﬁlam
bisbenzimide (nuclei). The images at the right show the same ﬁelds with merged images in w
starred arrows point to GFAP-immunoreactive cells in which translocation occurred; the ﬁlle
the non-ﬁlled arrows point to cells that lack GFAP immunoreactivity but in which translocati
which nuclear translocation occurred. The bar=50μm.myenteric glia/neuron ratios in both the duodenum (Fig. 1I) and ileum
(Fig. 1J) inWTmicewere compared to those in the same regionsofNSE–
Nog/+ animals. In both the duodenum and the ileum, the myenteric
glia/neuron ratios were signiﬁcantly higher in WT than in NSE–Nog/+
mice (pb0.001). This was also true of the submucosal (Fig. 1K; pb0.01)
glia/neuron ratios although the submucosal plexuswas analyzed only interic glia. The ability of BMP4 to induce the phosphorylation and nuclear translocation of
rat gut with antibodies to p75NTR. Cultures were starved for 6 h prior to the test exposure
lation and nuclear translocation were detected with antibodies that recognize the
sly identiﬁed with antibodies to GFAP. A. The proportions of GFAP-immunoreactive glia
cultures treated with vehicle, BMP4, or BMP4+noggin. Because of themagnitude of the
1/5/8 was signiﬁcantly greater (pb0.001) in cultures exposed to BMP4 than in those
nslocation of pSmads. These effects are illustrated for cultures exposed to vehicle (B, C),
entous green immunoﬂuorescence of GFAP and blue ﬂuorescence of DNA stained with
hich the red immunoﬂuorescence of pSmad 1/5/8 is superimposed on that of GFAP. The
d arrows point to GFAP-immunoreactive cells in which translocation has not occurred;
on occurred. The arrowwith a tail points to a dividing GFAP-immunoreactive glial cell in
Fig. 5. Transcripts encoding ErbB3 can be detected in rat fetal bowel and immunoisolated
ENCDC. RNA was extracted from the whole bowel at E12, E17, and P1 and from ENCDC
immunoselected from the gut at E15 with antibodies to p75NTR. RT-PCR was used to
analyze expression of ErbB3. A. Transcripts encoding ErbB3 were detected in the whole
gut at each age examined. Note that no products of ampliﬁcation appeared in controls
when RT was omitted (RT-). B. Transcripts encoding ErbB3 were found primarily in
immunoisolated ENCDC (CD), although some can also be found in negatively
immunoselected non-crest-derived cells (nCD). Despite the negative selection, the nCD
preparation contained some residual transcripts encoding p75NTR and thus was slightly
contaminated with ENCDC.
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(examined in the ileum) did not differ signiﬁcantly from one another in
either plexus, but both were lower than those of WT littermates. These
data suggest that BMP signaling promotes development of glia, which
are thus reduced both in absolute numbers and relative to neuron
numbers when BMP signaling is antagonized by the NSE-directed
overexpression of noggin.
Transgenic overexpression of BMP4 enhances development of enteric glia
The effects of transgenic overexpression of BMP4were determined
to test the hypothesis, suggested by the overexpression of noggin, that
BMP signaling promotes enteric glial development. Laminar prepara-
tions of the duodenal wall were examined using immunocytochem-
ical detection of S100 as a glial marker (Figs. 2A, B). The packing
densities of enteric glia and the glia to neuron ratios weremeasured in
the myenteric plexus of WT and NSE–BMP4/+ mice after immunos-
taining glia with antibodies to S100β and light counterstaining
neurons with cuprolinic blue (Fig. 2A inset). Only heterozygous
NSE–BMP4/+ mice were studied because sufﬁcient numbers of
surviving homozygotes could not be obtained. Both the glial packing
density (Fig. 2C; pb0.0005) and the glia/neuron ratio (Fig. 2D;
pb0.0001) in NSE–BMP4/+ animals were signiﬁcantly greater than
those of WT littermates. These observations are consistent with those
obtained from studies of NSE–Nog mice and together they suggest
that BMP signaling promotes enteric glial development in vivo.
BMPs promote enteric glial differentiation in vitro
To determine whether the effects of BMPs on glial precursors are
direct or indirect and to deﬁne when, during development, gliogen-
esis is BMP-dependent, ENCDC were isolated from fetal rat gut at E12,
E14, and E16 and exposed to BMP-2 or 4 in vitro. Immunoselection
with antibodies to p75NTR was used to obtain ENCDC and immuno-
cytochemistry for BFABP, S100β, and GFAP was employed to identify
cells developing in a glial lineage. BFABP appears before S100β and
GFAP during ENS development (Young et al., 2003) and thus was used
to detect cells committing early (E12) to a glial lineage (see
Supplemental Fig. 1), while GFAP (Figs. 3B–D) and S100β (Fig. 3E)
were used to detect more mature glia at later ages. Since effects of
low and high concentrations of BMPs on neuronal differentiation
differ in vitro (Chalazonitis et al., 2004), we examined the effects on
gliogenesis of ﬁve days of continuous exposure of ENCDC to both low
(0.5–1 ng/ml) and high (20 ng/ml) concentrations of BMP4. At both
E12 and E14 the high, but not the low concentration of BMP4
signiﬁcantly increased numbers of glia (Fig. 3A; E12: pb0.05; n=18;
E14: pb0.001; n=18). The effects of BMP4 were signiﬁcantly greater
in cells isolated at E14 than in those isolated at E12 (pb0.01). In
contrast, at E16, only the low dose of BMP4 altered gliogenesis
(pb0.05; n=36); moreover, the effect was signiﬁcantly smaller than
at E14 (pb0.01). These observations are consistent with a direct effect
of BMP signaling on ENCDC to promote glial development but the
efﬁcacy of BMP-promoted gliogenesis is developmentally regulated. It
is to be noted that concomitant to the differentiating effect on glia,
high BMP treatment also decreased total cells to 72.5±19% that of
vehicle-treated cultures, an effect previously reported (Chalazonitis
et al., 2004).
BMP receptor activation leads to the phosphorylation and nuclear
translocation of receptor-activated Smad proteins (ten Dijke et al.,
2002). The nuclear translocation of phosphorylated Smad1/5/
8 (pSmad) was thus investigated immunocytochemically to deter-
mine whether differentiated enteric glia respond directly to BMP4
stimulation. ENCDC were immunoselected at E16 and cultured for
5 days to accumulate a sufﬁcient number of glial cells to examine. A
low concentration of BMP4 was ﬁrst added to the medium (3 days) to
enhance glial differentiation and to promote ErbB3 expression, whichis necessary for development of enteric glia (Riethmacher et al., 1997).
GGF2 was then applied to maximize glial numbers (last 2 days).
Following this treatment, cultures were always starved for 6 h in a
medium that lacked GFF2, insulin, basic ﬁbroblast growth factor, and
epidermal growth factor in order to minimize possible interference
with Smad translocation evoked by ongoing activity in the ERK
pathway (Kretzschmar et al., 1997) prior to provoking them with a
test concentration of BMP. Translocation was thus studied in the
absence of GGF2. Cultures were exposed for 1 h either to vehicle
(Figs. 4B, C) or a high concentration of BMP4 (20 ng/ml) to ensure that
BMP receptors would be saturated (Chalazonitis et al., 2004).
(Figs. 4D, E) or BMP-4+noggin (100 ng/ml) (Figs. 4 F, G). BMP4
exposure signiﬁcantly (almost 20-fold) increased the nuclear trans-
location of phosphorylated Smad1/5/8 in GFAP-immunoreactive cells
(Fig. 4A). This increase was speciﬁc in that it was abolished by noggin
(100 ng/ml). These data support the idea that enteric glia are BMP-
responsive.
ErbB3 is expressed in the fetal bowel
RT-PCR was used to determine whether transcripts encoding
ErbB3 are present in developing fetal rat gut and isolated ENCDC. RNA
was extracted from the bowel at E12, E17, and P1. At E12, neuronal
development is well underway but glia cannot yet be recognized
(Rothman and Gershon, 1982; Young et al., 2003); by E17, both early
and late-born neurons have appeared and glial development has
begun. By P1, the ENS has matured sufﬁciently well to enable the gut
to function well enough to support oral feeding. Transcripts encoding
ErbB3were detected in the whole gut as early as E12 and continued to
be expressed through P1 (Fig. 5A). Transcripts encoding ErbB3 were
also detected in E15 ENCDC isolated by immunoselection with
antibodies to p75NTR (Fig. 5B) and in the fraction of negatively
selected cells from dissociated bowel that were not bound to beads
coated with antibodies to p75NTR (Fig. 5B); however, because p75NTR
transcripts were detected in this fraction, it must have contained
some ENCDC (Fig. 5B, middle panel). The abundance of transcripts
encoding ErbB3 in isolated fractions paralleled the abundance of
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idea that ENCDC express ErbB3, although they do not exclude the
possibility that ErbB3 might also be expressed by some bowel wall
cells that are not of crest origin.
Immunocytochemistry was used to locate cells that express ErbB3
in the mouse fetal and adult gut wall. These experiments were carried
out in conjunction with appropriate antibodies to locate ENCDC,
neurons and glia. Double label immunocytochemistry with antibodies
to ErbB3 and cell type-speciﬁc markers could not be carried out in
fetal bowel because antibodies raised in different species were not
available. The immunoreactivity of p75NTR outlined the region in the
outer bowel mesenchyme in which development of primordial
myenteric ganglia occurs (Fig. 6A). This is the same region that also
contained ErbB3-immunoreactive cells, HuC/D-immunoreactive neu-
rons (Figs. 6B, C), and both BFABP- (Fig. 6D) and S100β-immunore-
active glia (Fig. 6E). The ErbB3-immunoreactive cells were found to be
adjacent to developing neurons, withwhich they partially overlapped,
but the cells expressing ErbB3 immunoreactivity were concentrated
in a band of the fetal bowel that was just serosal to most of the
developing neurons (Figs. 6B, C). The location of ErbB3-immunore-
active cells in relation to those of neurons and glia was also
investigated in the adult bowel to determine whether the associationFig. 6. ErbB3 immunoreactivity is restricted in the gut wall to developing and mature elemen
mouse intestine in relation to cells of neural crest origin (p75NTR-immunoreactive), neurons
S100β and in adult bowel with antibodies to GFAP). Nuclei were counterstained with bisb
(arrows) that will develop into the ganglia of the myenteric plexus. B. E17. ErbB3 immunor
immunoreactive cells are found in a band (arrow) that is adjacent to the neurons (arrow
magniﬁcation, the ErbB3-immunoreactive cells (red; arrow) can be identiﬁed serosal to n
D. E17. BFABP (green) immunoreactivity is demonstrated to determine the location of cells d
(arrow; compare with panel A and B). E. E17. Glia are demonstrated with antibodies to S10
Some cells (green) can be seen internal to the circular muscle in the submucosa. F. Adult. Mo
antibodies to ErbB3 (red immunoﬂuorescence) for double label immunocytochemistry. Erb
(arrows) that lack HuC/D immunoreactivity. ErbB3 and HuC/D immunoreactivities are also co
D but lack ErbB3 immunoreactivity (submucosal plexus; concave arrowhead). G–I. Adult. C
polyclonal antibodies to ErbB3 (H; red immunoﬂuorescence) for double label immunocytoch
(arrow). Some neurons also show ErbB3 immunoreactivity. Bars A, B, D, and E=50 μm; C,of ErbB3 with the primordial myenteric plexus was maintained as the
ENS matured. Chicken antibodies to GFAP were found to react with
adult enteric glia (Figs. 6G, I), although they did not do so when
applied to section of fetal gut. These antibodies made it possible to
determine directly whether ErbB3 is expressed in glia. In the adult
bowel, ErbB3 immunoreactivity was exclusively located within the
ganglia of the myenteric and submucosal plexuses (Fig. 6F). Coinci-
dent localization of ErbB3 with GFAP immunoreactivity implies that
glia express ErbB3 (Figs. 6G, H, I). A subset of enteric neurons was also
found to be ErbB3-immunoreactive (Figs. 6F, I), although most ErbB3
expression in enteric ganglia was in non-neuronal cells (Fig. 6F). The
association of ErbB3-immunoreactive cells with the developing and
mature ENS and their expression in mature enteric glia and a subset of
neurons is consistent with the ideas that ErbB3-mediated signaling
contributes to gliogenesis and may also be involved in the develop-
ment and/or function of a subset of enteric neurons.
Enteric GGF2 expression follows that of ErbB3
Since, GGF2, is potentially a gliogenic ligand for ErbB3 in the
developing rat gut, we used quantitative RT-PCR to deﬁne expression
of GGF2 in the fetal bowel as a function of gestational age (Fig. 7).ts of the ENS. ErbB3 was located immunocytochemically in sections of E17 and mature
(HuC/D-immunoreactive), and glia (marked in fetal gut with antibodies to BFABP and
enzimide. A. E17. p75NTR immunoreactivity (red). ENCDC have begun to form clusters
eactivity (red) and HuC/D immunoﬂuorescence (green) are demonstrated. The ErbB3-
head) and concentrated on their serosal side. (Compare with panel A). C. At higher
eurons (green; arrow head). Partial overlapping of cells occurs (yellow ﬂuorescence).
eveloping in a glial lineage. These cells are found in the region of the developing ganglia
0β. Again, the cells are located in the region of developing myenteric ganglia (arrows).
noclonal antibodies to HuC/D (green immunoﬂuorescence) were combined with rabbit
B3-immunoreactive cells can be found in both the myenteric and submucosal plexuses
incident in some neurons (arrowhead, myenteric plexus), whereas others display HuC/
hicken antibodies to GFAP (G; green immunoﬂuorescence) were combined with rabbit
emistry (I; merge). Coincident immunoreactivity is found in GFAP-immunoreactive glia
F–I=25 μm).
Fig. 7. The enteric abundance of transcripts encoding GGF2 is developmentally
regulated. Real-time PCR was used to quantify transcripts encoding GGF2 in the fetal
and postnatal rat bowel as a function of age. Transcripts were detected as early as E12
and increased signiﬁcantly through E17. Following a perinatal decline in abundance,
transcripts encoding GGF2 increased again reaching levels in the adult gut that were
comparable to those achieved at E17. *pb0.001.
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the earliest time examined. The abundance of such transcripts at E12
was low but increased signiﬁcantly between E12 and E14 and
continued to increase signiﬁcantly through E17, when GGF2 expres-
sion peaked. The abundance of transcripts encoding GGF2 decreased
signiﬁcantly perinatally, but increased again in the adult bowel to a
level that was equivalent to that at E17. Because ErbB3 is already
expressed in the E12 gut, cells with the potential to respond to GGF2
are present in the bowel during the period (E12–E17) when GGF2
expression is maximal.
GGF2 stimulates enteric gliogenesis in vitro
GGF2was added to isolated ENCDC to test the hypothesis that GGF2
promotes thedevelopment/survival of enteric glia. ENCDCwere isolated
from the fetal rat gut at E12, E14, E15, and E16 by immunoselectionwith
antibodies to p75NTR. BFABP, S100β, and GFAP were used as glial
markers. GGF2 (100 ng/ml) increased the numbers of enteric glial cells
differentiating in vitro in an age-dependent fashion. Although GGF2
signiﬁcantly increased gliogenesis in ENCDC isolated at E12 (250±29%
vehicle; pb0.01) and E14 (351±37% vehicle; pb0.001), themagnitude
of the effect increased exponentially between E14 and E15. No further
increase was seen between E15 and E16, but at both ages GGF2-
promoted gliogenesis was signiﬁcantly greater than at E12 or E14
(Fig. 8A). At E16, moreover, GGF2 signiﬁcantly increased the proportion
of p75NTR-immunoreactive cells that coincidentally expressed GFAP
(Figs. 8B–H). This latter observation suggests that GGF2 favors
gliogenesis at the expense of neurogenesis because p75NTR immuno-
reactivity is maintained when ENCDC differentiate into glia but not
when they develop as neurons (Young et al., 2003). By comparison at
E16, GGF2 increased the total number of non-glial cells in ENCDC
cultures to 158±19% vehicle, the number of p75NTR-immunoreactive
cells to 207±36% vehicle, but the number of glia (GFAP-immunoreac-
tive) to 4824±675%vehicle. The proportion of p75NTR-immunoreactiveFig. 8. GGF2 promotes gliogenesis in vitro and inhibits GDNF-driven neurogenesis. A. GGF2 e
function of age in ENCDC isolated from rat fetal gut at E12–E16. BFABP, detected immunocyt
employed to identify glia at E14–16. B. ENCDC were isolated from the fetal bowel at E16
increases the proportion of ENCDC developing as glia. Antibodies to p75NTR were used to ide
p75NTR and GFAP immunoreactivities in cultures of ENCDC exposed either to vehicle (C–E)
(green ﬂuorescence). D. Vehicle exposure, GFAP immunoreactivity (red ﬂuorescence). E. V
exposure, GFAP immunoreactivity. H. GGF2 exposure, merged image. I–J. The effects on glio
ENCDC immunoselected at E12. Antibodies to BFABP were used to detect glia while neuron
number of cells in each culture developing as neurons plus glia. J. Neurons, as a proportion of
on gliogenesis and neurogenesis of GGF2 and GDNF, applied individually or in combination t
plus glia. L. Neurons as a proportion of the total number of neurons plus glia.cells in the cultures that were identiﬁable as glia (GFAP-immunoreac-
tive), moreover, increased in the presence of GGF2 to 436±11% vehicle
(Fig. 8B). The GGF2-induced increase in glia thus transcends whatever
increase GGF2 might also provoke in other types of cell.
The effects of GGF2were then comparedwith those of GDNF, which
has previously been shown to promote neurogenesis in cultures of
ENCDC (Chalazonitis et al., 1998a, 2004). GDNF was applied to cultures
by itself or in combination with GGF2. At E12, GGF2 weakly promoted
gliogenesis and GDNF co-treatment inhibited GGF2-promoted gliogen-
esis (Fig. 8I). In contrast, GDNF promoted neurogenesis and GGF2 was
unable to oppose the neuron-promoting action of GDNF (Fig. 8J). At E16,
however, GGF2 strongly stimulated gliogenesis and GDNF co-treatment
no longer blocked the GGF2-promoted gliogenesis (Fig. 8K). At E16
GDNF still promoted neurogenesis, but at this age GGF2 co-treatment
inhibited the neuron-promoting effect of GDNF (Fig. 8L). These
observations suggest that GGF2 and GDNF exert opposing effects on
the divergence of enteric glia and neurons, with GGF2 favoring
gliogenesis and GDNF favoring neurogenesis. These effects are age-
dependent. At E16, the pro-glial effects of GGF2 predominate over
GDNF-promoted neurogenesis whereas at E12 the pro-neuronal effects
of GDNF predominate.GGF-2 promotes glial proliferation and GGF2-dependency
To determine whether GGF2 stimulates the proliferation of
committed glial cells in vitro, ENCDC were isolated from rat fetal gut
at E15 when GGF2-promoted gliogenesis is maximal (see Fig. 8A) and
were examined immunocytochemically for the proliferation marker
phosphohistone 3 (PH3) and for GFAP. Exposure to GGF2 for 5 days
signiﬁcantly increased the proportion of cells doubly labeled with
antibodies to PH3 and GFAP (Figs. 9A–C) in a concentration-dependent
manner (Fig. 9C). TodeterminewhetherGGF2alsopromoted survival of
enteric glia, ENCDC were isolated at E15 and allowed to develop for
5 days in the continuous presence of GGF2 (100 ng/ml) or vehicle. Far
fewer cells acquired GFAP immunoreactivity in the vehicle-treated
cultures, than in those exposed to GGF2; moreover, the proportion of
glia undergoing apoptosis was signiﬁcantly higher in vehicle- than in
GGF2-treated cultures (17.6%±3.7% vs. 4.04%±0.6%; pb0.02). To study
the effects of GGF2withdrawal, ENCDCwere exposed for 3 days toGGF2
and then were deprived of it for the ﬁnal 2 days of the 5-day culture
period. Non-apoptotic glia (cytoplasmic red ﬂuorescence, Fig. 9D) and
those displaying apoptosis (Figs. 9E, F), which was assessed by the
TUNEL method (nuclear green ﬂuorescence), were then quantiﬁed.
Withdrawal from GGF2 signiﬁcantly decreased the number of non-
apoptotic glia (Fig. 9D) and signiﬁcantly increased the number of
apoptotic glial cells (Figs. 9E, H). Because BMP signaling increases the
dependency of some ENCDCs on growth factors (Chalazonitis et al.,
2004), the effects of BMP4 on the GGF2-dependence of glial cells were
examined. Addition of BMP4 for the ﬁrst 3 days of culture enhanced the
effects of GGF2 withdrawal; two days after withdrawing GGF2 the
number of non-apoptotic glia declined signiﬁcantly (Fig. 9D) and the
number of apoptotic glia increased (Figs. 9E, H). In contrast cultures
maintained with GGF2 for the last 2 days exhibited low numbers of
apoptotic glia (Figs 9E, F, and G). Although prior exposure to BMP4 did
not alter the percentage of GFAP-immunoreactive cells undergoingnhances gliogenesis when added to ENCDC in vitro. The efﬁcacy of GGF2 increases as a
ochemically, was used as a glia marker at E12 while antibodies to S100β and GFAP were
and cultured for 5 days in the presence of either vehicle or GGF2. GGF-2 signiﬁcantly
ntify ENCDC and antibodies to GFAP were used to detect glia. C–H. Illustrations showing
or to GGF2 (F–H). The markers=20 μm. C. Vehicle exposure, p75NTR immunoreactivity
ehicle exposure, merged image. F. GGF2 exposure, p75NTR immunoreactivity. G. GGF2
genesis and neurogenesis of GGF2 and GDNF, applied individually or in combination to
s were detected with antibodies to HuC/D or PGP9.5. I. Glia, as a proportion of the total
the total number of cells in each culture developing as neurons plus glia. K–L. The effects
o ENCDC immunoselected at E16. K. Glia as a proportion of the total number of neurons
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Fig. 9. GGF2 stimulates enteric glial proliferation and GGF2-dependency. ENCDC were isolated from fetal rat gut at E15 and glial development was assayed in vitro using GFAP
immunoreactivity (redﬂuorescence) as a glialmarker. PH3 immunoreactivity (greenﬂuorescence)was used to identify proliferating cells, and bisbenzimide (blueﬂuorescence)was used
to counterstain DNA. A, B. Cells were exposed to GGF2 (100 ng/ml) for 5 days. GFAP-immunoreactive cytoplasm surrounds the PH3-immunoreactive chromosomes of dividing glia. In the
merged image, the color of the chromosomes is aqua because they have been counterstainedwith bisbenzimide. The bar=10 μm. C. The graph shows that the ability of GGF2 to increase
the proliferation of GFAP-immunoreactive glia is concentration-dependent. D. Signiﬁcantly more non-apoptotic glia are found in cultures exposed to GGF2 (100 ng/ml) continuously for
5 days than in cultures inwhich GGF2 was withdrawn for the ﬁnal 2/5 days of incubation. The co-addition of BMP2 or 4 (20 ng/ml) for the ﬁrst 3 days of culture did not alter the effect of
GGF2 withdrawal on the proportion of non-apoptotic glial cells found in the cultures. E–H. The TUNEL method (green ﬂuorescence in panels G and H) was used to assess apoptosis and
coincidencewith GFAP immunoreactivity (red ﬂuorescence in panels G and H) to identify apoptotic glia. Signiﬁcantly fewer apoptotic glial cells (E) are found in cultures exposed to GGF2
(100 ng/ml) continuously for 5 days than in cultures inwhich GGF2 was withdrawn for the ﬁnal 2/5 days of incubation. F. The co-addition of BMP-2 or 4 (20 ng/ml) for the ﬁrst 3 days of
culture increased theeffect of GGF2withdrawalon theapoptosis of glial cells found in thecultures. This effectwasmasked (E)whenapoptosiswasexpressedasa%of cells expressingGFAP,
but is evident (F)when apoptotic gliawere quantiﬁed as a proportion of total cells. G. Culture exposed toGGF2 (100 ng/ml)+BMP-2 for the ﬁrst 3/5 days and thenmaintainedwith GGF2
for the last 2/5 days. H. Same as in (G) except that GGF2 is withdrawn for the ﬁnal 2/5 days of incubation. The bar (G, H)=50 μm.
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the overall number of apoptotic glia (TUNEL+/GFAP+) expressed as a
proportion of total cells in each culture (Figs. 9F–H). These observations
suggest that GGF2 stimulates proliferation and enhances the survival of
enteric glia developing in vitro;moreover, glia becomeGGF2-dependent
and this dependence is enhanced by prior exposure to BMPs.BMP signaling promotes ErbB3 expression
Experiments described above demonstrate that BMP and GGF2
signaling both stimulate enteric gliogenesis. Since BMP signaling can
induce expression of growth factor receptors by ENCDCs (Chalazonitis
et al., 2004), it is possible that increased expression of ErbB3mediates
76 A. Chalazonitis et al. / Developmental Biology 350 (2011) 64–79the gliogenic response to BMPs. To test this idea, ENCDC were isolated
from fetal rat gut at E14 by immunoselection with antibodies to
p75NTR, cultured for 5 days with vehicle or in the continuous presence
of BMP4 (0.5 ng/ml or 20 ng/ml) and ErbB3 was detected immuno-cytochemically. The high, but not the low concentration of BMP4
signiﬁcantly increased the proportion of cells in the cultures that
expressed ErbB3 immunoreactivity (Fig. 10A). BMP4 treatment also
increased the proportion of cells expressing GFAP immunoreactivity,
77A. Chalazonitis et al. / Developmental Biology 350 (2011) 64–79which co-localized with that of ErbB3 (Fig. 10B). BMP4 thus enhanced
the percentage of cells undergoing glial differentiation. This effect was
seen in experiments in which ENCDC were immunoisolated at E14
and cultured for 5 days in the presence of vehicle or GGF2 (100 ng/
ml), with or without BMP4 (20 ng/ml). When BMP4 and GGF2 were
combined, however, cells were exposed to BMP4 only for the ﬁrst
3 days. GGF2 alone signiﬁcantly increased the numbers of GFAP-
expressing glial cells (pb0.001 vs. vehicle; Fig 10C) but co-treatment
with BMP4 prevented this increase (p b 0.05). The inhibitory effects
of BMP4 did not reﬂect decreased glial survival; the number of glial
cells undergoing apoptosis in cultures exposed to BMP4 plus GGF2
(8.6±2%) was not signiﬁcantly different from that in cultures
exposed only to GGF2 (4.0±0.6%) although the proportion of
apoptotic glia in each was signiﬁcantly less than that in cultures
exposed to vehicle (17.6±3.7%; pb0.001). The inhibitory effects of
BMP4 on GGF2-driven expansion of the glial population, therefore,
can be explained most parsimoniously as a reﬂection of the ability of
BMP4 to promote exit of ENCDC from the cell cycle. Although the
BMP-driven exit of GGF2-stimulated glia from the cell cycle has not
been demonstrated directly, such an action would be analogous to the
previously demonstrated effects of BMPs on development of neurons
from isolated ENCDC (Chalazonitis et al., 2004).
Pre-exposure and simultaneous exposure to BMPs exert different effects
on GGF2-driven gliogenesis
Because the simultaneous exposure of ENCDC to both GGF2 and
BMP4 resulted in the development of signiﬁcantly fewer glial cells
than exposure to GGF2 alone, the effect of pre-exposure to BMP4 was
investigated. BMP4 promotes expression of ErbB3; therefore, a pre-
exposure to BMP might, by increasing ErbB3 expression in ENCDC,
provide a larger number of potential targets primed to respond to
subsequent GGF2 exposure. ENCDC were immunoisolated from fetal
rat gut at E16 and exposed to BMP4 (1 ng/ml) or to vehicle for 3 days.
The cultured cells were then washed, exposed for 2 additional days to
GGF2 (100 ng/ml), and examined for GFAP and the transcription
factor Sox10 immunoreactivity. Pretreatment with BMP4 signiﬁcantly
increased the proportion of cells expressing GFAP immunoreactivity.
Measured as fold-enhancement over vehicle pretreatment, the BMP4-
induced increment in GGF2-stimulated GFAP expressionwas 9.7±0.9
(pb0.0001). Pre-exposure to BMP4 also increased the proportion of
cells doubly labeled with antibodies to Sox10 and GFAP (see
Supplemental Fig. 2). Because Sox10 is expressed in uncommitted
ENCDC and retained in glia, the proportion of immunoisolated ENCDC
in which Sox10 and GFAP immunoreactivities are coincident reﬂects
the degree to which the ENCDC with a gliogenic potential have become
committed to a glial lineage. This proportion was 50.0%±3.4% in
cultures that were pre-exposed only to vehicle prior to incubation with
GGF2 but 80.0%±5.2% in cultures that were pre-exposed to BMPs
(pb0.003). Pre-exposure toBMPs thus increases thegliogenic efﬁcacyof
subsequent exposure to GGF2.
Discussion
We tested the hypothesis that growth factors secreted by the
enteric mesenchyme regulate the differentiation of uncommittedFig. 10. Exposure to BMPs promote the in vitro differentiation of cells that express ErbB3. EN
low (0.5 ng/ml) concentration of BMP4 signiﬁcantly enhanced expression of ErbB3. In the
expressing both ErbB3 and GFAP was also signiﬁcantly increased. B. Cultures exposed to vehi
only to vehicle (Veh), few cells show coincidence of ErbB3 and GFAP immunoreactivities (
presence of neighboring cells in the culture that show little or no ErbB3 or GFAP immunore
BMP), however, many cells express the immunoreactivities of ErbB3 (red) and GFAP
immunoﬂuorescence is merged). In the lower set of panels DNA is counterstained with bisb
ErbB3 immunoﬂuorescence, and both the immunoﬂuorescence of ErbB3 and GFAP. These cu
The marker=50 μm. C. GGF2 promotes the proliferation of ENCDC that are able to give rise t
concentration of BMP4.neural/glial precursors in the ENCDC population that colonizes the
bowel. Speciﬁcally, we proposed that BMPs induce ENCDC to become
committed and acquire responsiveness to the neurogenic effects of
GDNF or to the gliogenic actions of GGF2. A consequence of this
hypothesis is that BMPs would be essential not only for development
of the neuronal component of the ENS, as previously established
(Chalazonitis et al., 2004, 2008), but for the glial component as well. In
fact, mice that overexpress noggin under the control of the NSE
promoter, which interferes with BMP2- or BMP4-mediated responses
in the primordial ENS (Chalazonitis et al., 2004, 2009), were found to
have fewer glia and a depressed glia/neuron ratio, whereas,
conversely, mice that overexpress BMP4 had more glia and an
enhanced glia/neuron ratio. These observations conﬁrm that BMP
signaling is important in enteric gliogenesis. Interference with BMP
signaling distorts the glia/neuron ratio in favor of neurons, suggesting
that BMP signaling may be even more important in the development
of enteric glia than in enteric neurogenesis. BMP signaling in neural
crest stem cells had previously been reported to promote neurogen-
esis rather than gliogenesis (Shah and Anderson, 1997). ENCDC,
however, have already migrated to the gut and thus are not identical to
premigratory neural crest stem cells. Crest-derived cells that migrate to
the gut are subjected to a variety of microenvironmental inﬂuences as
they traverse their migratory pathway to and within the bowel. ENCDC
thus express a number of genes, such as ret (Pachnis et al., 1993), that
their premigratory ancestors in the crest do not; moreover, premigra-
tory crest cells express genes, such as slug/snail (Sauka-Spengler and
Bronner-Fraser, 2008), which ENCDC do not express. Secreted factors,
such as the BMPs, which are important in the dorsalization of the neural
tube to form the neural crest (Liemet al., 1995) and the segmentation of
the enteric mesenchyme (Roberts, 2000), can thus be utilized for a
variety of purposes at different times and locations in an embryo.
Treatment of cultured ENCDC with BMP2 or BMP4 demonstrated
that BMP signaling directly promotes the development of enteric glia
and does so in a concentration-dependent and developmentally
regulated manner; ENCDC were maximally sensitive to BMP-promoted
gliogenesis when immunoisolated from E14 rat gut. That cultured
ENCDC respond directly to BMPs was also evident in the ability of BMPs
to induce nuclear translocation of phosphorylated SMADproteins (Chen
et al., 2004). BMP signaling thus enhances formation of both neurons
and glia during ENS development, suggesting that BMP signaling is by
itself insufﬁcient to account for the ultimate divergence of enteric
neuronal and glial lineages. We therefore tested the idea that BMP
enhances glial development by promoting expression of ErbB3 by
ENCDC and thus the responsiveness of cells to GGF2.
Isolated ENCDC were found to express transcripts encoding ErbB3
and also to exhibit ErbB3 immunoreactivity. This observation is con-
sistent with the idea that ErbB3 signaling is involved in gliogenesis.
ErbB3-immunoreactive cells were conﬁned to the region of the
developing myenteric plexus. This region was identiﬁed immunocyto-
chemically with antibodies to markers of ENCDC (p75NTR), neurons
(HuC/D), and glia (BFABP, and S100β). Interestingly, the location of
ErbB3-immunoreactive cells was adjacent to and partially overlapping
with that of neurons; however, ErbB3-immunoreactive cells were
strikingly concentrated on the serosal side of the neurons. The
association of ErbB3 immunoreactivity within the ENS (both myenteric
and submucosal plexuses) persisted in the adult gut, where it wasCDC were isolated from fetal rat gut at E14. A. Exposure to a high (20 ng/ml), but not a
same cultures, the development of cells expressing the glial marker, GFAP, and cells
cle (top 3 panels) or a high concentration of BMP4 (lower 6 panels). In cultures exposed
arrows); nuclear ﬂuorescence of DNA, counterstained with bisbenzimide, reveals the
activities. The bar=10 μm. In cultures treated with a high concentration of BMP4 (Hi
(green), which are for the most part coincident (yellow when ErbB3 and GFAP
enzimide (blue) and images are illustrated in which DNA ﬂuorescence is merged with
ltures also illustrate the tendency of ENCDC to aggregate following exposure to BMPs.
o glia. This GGF2-driven proliferation is signiﬁcantly inhibited by co-exposure with high
78 A. Chalazonitis et al. / Developmental Biology 350 (2011) 64–79possible to determine that ErbB3 immunoreactivitywas coincidentwith
that of GFAP and thus was present in enteric glia. ErbB3 immunoreac-
tivitywas also found in a subset ofHuC/D-immunoreactive neurons. The
serosa-facing orientation of ErbB3 immunoreactive cells, however, was
lost in the ganglia of the mature intestine. It is possible that the serosa-
facing orientation of ErbB3-immunoreactive cells in the fetal mouse gut
reﬂects its expression in cells that have not yet become committed to
neuronal or glia lineages. The E17 mouse gut contains many dividing
ENCDC that are presumably uncommitted (Chalazonitis et al., 2008;
Phamet al., 1991). The recent observation that neurogenesis in adult gut
occurs in specialized sites that are located serosal to neurons in adult
intestine (Liu et al., 2009) is consistent with the idea that ENCDC
precursors persist serosal to mature neurons and glia. These observa-
tions thus are consistent with the idea that ErbB3-mediated signaling
participates in gliogenesis, but they also suggest that ErbB3 may be
involved in the development and/or function of a subset of enteric
neurons. ErbB3 expression has also been observed in a subset of CNS
neurons (Thompson et al., 2007) and ErbB3 is important in the
development of dorsal root and sympathetic ganglia (Britsch et al.,
1998; Honjo et al., 2008).
The fetal bowel,moreover, contained transcripts encoding the ErbB3
ligand, GGF2. GGF2 expression was detected in fetal rat gut as early as
E12 but increased signiﬁcantly at E14 and E16. GGF2 expression in the
developingbowel thus lagsbehind that ofGDNFand correspondswell in
its timing to the abilities of BMPs andGGF2 to promote gliogenesis from
isolated ENCDC, both of which were found to increase signiﬁcantly
betweenE12 andE14. GGF2 increasedproliferation of glial precursors as
well as their commitment to a glial lineage; therefore, addition of GGF2
to cultures of ENCDC immunoselected from fetal rat gut skewed theglia/
neuron ratio toward glia. Conversely, GDNF treatmentof ENCDCskewed
the developing glia/neuron ratio toward neurons. At E12, cultures
tended to bemore responsive to GDNF, in that GDNF-induced neuronal
development was not inhibited by co-addition of GGF2 and the co-
addition of GDNF prevented GGF2-simulated glial development. In
contrast, at E16, when GGF2 expression in vivo is maximal, the co-
addition of GGF2 counteracted the enhancement of neurogenesis by
GDNF and GDNF no longer inhibited GGF2-mediated gliogenesis. These
data are consistent with prior observations that GDNF inhibits
gliogenesis in ENCDC cultures (Chalazonitis et al., 1998a), an observa-
tion that was interpreted to mean that GDNF is unable to maintain glial
progenitors. Alternatively, this might reﬂect the ability of GDNF to skew
development of E14–16 ENCDC toward neurons.
Survival of committed cells often requires continued ligand stimula-
tion of receptors that cells acquire as a result of their differentiation. By
promoting commitment of ENCDC precursors, therefore, BMPs might
induce cells to become dependent on particular growth factors for
survival. BMPs have been demonstrated, for example, to promote the
expression of TrkC by a subset of ENCDC; this subset of cells becomes
responsive to NT-3 and dependent on it for survival (Chalazonitis et al.,
2004). We therefore questioned whether BMPs, by promoting ErbB3
expression in developing ENCDC, render the cells not only GGF2-
responsive, but also GGF2-dependent. In fact, glia developing in vitro
from immunoisolated ENCDCunderwent apoptosis uponwithdrawal of
GGF2 indicating that newly-generated glia are GGF2-dependent. When
GGF2 was withdrawn following the co-exposure of immunoisolated
ENCDC to BMPs, the proportion of total cells in the cultures represented
byapoptotic glia increased signiﬁcantly. BMPs thus increased theoverall
GGF2-dependency of glial cells developing from ENCDC. This increase,
however, was not apparent when the numbers of apoptotic glia were
expressed as a percent of total glia, probably because BMP signaling also
decreased glial proliferation.
In summary, the current investigation supports the concept that
BMPs promote the differentiation of ENCDC. Early in development,
this effect enhances the ability of GDNF to drive neurogenesis and to
suppress GGF2-promoted development of glia. Later in ontogeny,
BMP-promoted differentiation leads to an increased ErbB3 expressionand enhanced GGF2-driven enteric gliogenesis with downregulation
of the neurogenic response to GDNF. It thus appears that BMPs are
called upon to play multiple roles during development, exerting
different effects on cells depending on the time and site of their action.
In the bowel, BMPs are evidently important for the differentiation of
both neurons and glia. Because transgenic overexpression of the BMP
antagonist, noggin leads to an overabundance of neurons and a
reduction of glia with a distortion of the neuron/glia ratio in favor of
neurons, it is likely that the direct involvement of BMPs in promoting
ErbB3 expression and consequent gliogenesis is required and cannot
be compensated for by other gliogenic factors such as the neuropoietic
cytokines (Chalazonitis et al., 1998b).
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